CN114729054A - 使用免疫检查点抑制剂抗体治疗癌症的方法和组合 - Google Patents

使用免疫检查点抑制剂抗体治疗癌症的方法和组合 Download PDF

Info

Publication number
CN114729054A
CN114729054A CN202180006543.2A CN202180006543A CN114729054A CN 114729054 A CN114729054 A CN 114729054A CN 202180006543 A CN202180006543 A CN 202180006543A CN 114729054 A CN114729054 A CN 114729054A
Authority
CN
China
Prior art keywords
antibody
antigen
binding fragment
ctla
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180006543.2A
Other languages
English (en)
Chinese (zh)
Inventor
J·库尔兰德
A·内格罗
S－C·常
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN114729054A publication Critical patent/CN114729054A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202180006543.2A 2020-05-12 2021-05-12 使用免疫检查点抑制剂抗体治疗癌症的方法和组合 Pending CN114729054A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063023554P 2020-05-12 2020-05-12
US63/023554 2020-05-12
PCT/EP2021/062695 WO2021228978A1 (en) 2020-05-12 2021-05-12 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies

Publications (1)

Publication Number Publication Date
CN114729054A true CN114729054A (zh) 2022-07-08

Family

ID=75977756

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180006543.2A Pending CN114729054A (zh) 2020-05-12 2021-05-12 使用免疫检查点抑制剂抗体治疗癌症的方法和组合

Country Status (12)

Country Link
US (3) US20210355224A1 (enExample)
EP (1) EP4021940A1 (enExample)
JP (2) JP7387912B2 (enExample)
KR (1) KR20230009354A (enExample)
CN (1) CN114729054A (enExample)
AU (3) AU2021269832B2 (enExample)
BR (1) BR112022021893A2 (enExample)
CA (1) CA3158607A1 (enExample)
IL (2) IL297640A (enExample)
MX (1) MX2022006728A (enExample)
TW (2) TW202535468A (enExample)
WO (1) WO2021228978A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024054897A1 (en) * 2022-09-07 2024-03-14 The University Of Chicago Methods for treating cancer with hyperactive adar enzymes
WO2025211692A1 (ko) * 2024-04-02 2025-10-09 (주)에트노바테라퓨틱스 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
WO2003087339A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
AU2003247337B2 (en) 2002-04-11 2007-09-06 Medimmune, Llc Preservation of bioactive materials by freeze dried foam
WO2003086443A1 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
WO2003087335A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
WO2004058156A2 (en) 2002-12-17 2004-07-15 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
LT3279215T (lt) 2009-11-24 2020-04-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
CA2964367C (en) * 2014-10-14 2024-01-30 Novartis Ag Antibody molecules to pd-l1 and uses thereof
EP3277318A1 (en) * 2015-04-01 2018-02-07 Medimmune Limited Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancer
CN109563171B (zh) * 2016-06-20 2023-09-19 F-星治疗有限公司 结合pd-l1和lag-3的结合分子
WO2018064013A1 (en) * 2016-09-27 2018-04-05 Peregrine Pharmaceuticals, Inc. METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR
KR20200020662A (ko) * 2017-04-03 2020-02-26 온콜로지, 인크. 면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
KR102693361B1 (ko) * 2017-05-26 2024-08-09 브루인 바이오사이언시스, 인크. 화학색전제
BR112019025188A2 (pt) * 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
WO2019241742A1 (en) * 2018-06-14 2019-12-19 Board Of Regents, The University Of Texas System Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer
WO2019239144A1 (en) * 2018-06-15 2019-12-19 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROBIN KATE KELLEY等: "Phase I/II study of durvalumab and tremelimumab in patients withunresectable hepatocellular carcinoma (HCC): Phase I safety andefficacy analyses", JOURNAL OF CLINICAL ONCOLOGY, vol. 35, 30 May 2017 (2017-05-30), pages 10 *

Also Published As

Publication number Publication date
AU2024266949A1 (en) 2024-12-19
WO2021228978A1 (en) 2021-11-18
US20240239893A1 (en) 2024-07-18
JP7387912B2 (ja) 2023-11-28
BR112022021893A2 (pt) 2022-12-20
IL297640A (en) 2022-12-01
AU2024202963B2 (en) 2025-11-20
KR20230009354A (ko) 2023-01-17
JP2024016209A (ja) 2024-02-06
AU2021269832B2 (en) 2024-09-19
AU2024202963A1 (en) 2024-05-30
IL311936A (en) 2024-06-01
AU2021269832A1 (en) 2022-05-19
EP4021940A1 (en) 2022-07-06
MX2022006728A (es) 2022-06-09
JP2023524359A (ja) 2023-06-12
US20220363762A1 (en) 2022-11-17
TW202207976A (zh) 2022-03-01
TWI870592B (zh) 2025-01-21
US20210355224A1 (en) 2021-11-18
TW202535468A (zh) 2025-09-16
CA3158607A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
JP2023080215A (ja) 肝細胞癌のための免疫療法
WO2020151759A1 (zh) 治疗肿瘤的联用药物组合物
WO2020187152A1 (zh) 治疗小细胞肺癌的联用药物组合物
AU2024202963B2 (en) Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies
WO2023217268A1 (zh) 抗tim-3抗体与抗pd-1抗体的药物组合
JP2024519907A (ja) 尿路上皮癌の治療における、免疫チェックポイント阻害剤と併用での抗体薬物複合体の使用
JPWO2019173523A5 (enExample)
WO2023174408A1 (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
WO2024051670A1 (zh) 结合tim-3的抗体与结合pd-1的抗体的药物组合
CN118697865A (zh) 治疗淋巴瘤的药物组合
CA3221817A1 (en) Combination therapies for the treatment of cancer
CN119894516A (zh) 用于治疗晚期实体瘤的组合物和方法
US20240317854A1 (en) Methods for treating cancer with anti-ilt3 antibodies
EA050171B1 (ru) Способы и комбинации для лечения рака с применением антител, являющихся ингибиторами иммунных контрольных точек
WO2023174278A1 (zh) 抗tim-3抗体与去甲基化药物的药物组合
WO2025087358A1 (zh) 抗体药物偶联物用于治疗癌症的方法
TW202527995A (zh) 抗b7h3抗體藥物偶聯物在製備治療鼻咽癌和/或肺淋巴上皮瘤樣癌的藥物中的用途
CN118681010A (zh) 用于治疗肺癌的药物组合
WO2023230554A1 (en) Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2025242190A1 (zh) 抗tigit抗体和抗pd-1抗体联合治疗肿瘤
CN118526572A (zh) c-Met激酶抑制剂和抗PD-1抗体-TGFβRII融合蛋白的药物组合
WO2023030532A1 (zh) 用于治疗食管癌的药物组合

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination